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Abstract
Background The aim of this study was to conduct a ret-
rospective database analysis to describe the chemotherapy
treatment patterns and outcomes of patients with gastric
cancer.
Methods Individuals diagnosed with gastric cancer were
identified from the IMS Oncology Database, which con-
tains electronic medical record (EMR) data collected from
a variety of community practices, and the Truven Health
MarketScan Research database, an administrative claims
database. Eligible patients were 18 years of age or older
and had an ICD-9 code 151.0–151.9. Patients were ex-
cluded if they had evidence of cancer within 6 months of
the index diagnosis.
Results There were 5257 eligible patients identified in
EMR data: 1982 (37.7 %) of these patients also had data
regarding chemotherapy treatments. Of the 1982 patients
who received first-line therapy, 42.3 %, 18.1 %, and 7.9 %
went on to receive a second, third, and fourth line of
chemotherapy, respectively. There were 11891 eligible
patients identified in the administrative database; 5299
(44.6 %) had data regarding chemotherapy. Of those ini-
tiating chemotherapy, 2888 (54.5 %) received a second
line and 1598 (30.2 %) received a third line of treatment.
The average total cost of care during first-line therapy was
$40,811 [standard deviation (SD) = $49,916], which was
incurred over an average of 53.5 (SD = 63.4) days. A
similar pattern was evident in second-line treatment (mean/
SD, $26,588/$33,301) over 41.2 (SD = 55.7) days.
Conclusions Costs and duration of care received vary
among gastric cancer patients in the U.S. There is a need to
understand which regimens may be associated with better
health outcomes and to standardize treatment as appropriate.
Keywords Stomach neoplasms  Outcome assessment 
Economics, medical  Retrospective studies
Introduction
Gastric cancer is the 5th most common cancer worldwide,
but is relatively less common in the United States (U.S.),
where it has the 16th highest incidence rate of all cancers.
In 2014, it is estimated that 22,220 new cases of gastric
cancer were diagnosed and 10,990 patients died of gastric
cancer [1]. Although those diagnosed with early-stage
disease may be cured of their disease, the prognosis for
most patients is poor. The 5-year relative survival rate for
patients diagnosed with localized disease is 64.1 %, but
this rate declines to only 4.2 % for those diagnosed with
metastatic disease [2]. Unfortunately, 80–90 % of patients
are diagnosed with advanced-stage disease [2] when sur-
gery and local therapies are no longer effective.
For patients with advanced or metastatic disease or for
postoperative therapy, the NCCN (National Comprehen-
sive Cancer Network) guidelines currently recommend the
use of platinum plus fluoropyrimidine as first-line therapy
[3]. Despite treatment, many patients experience disease
progression or recurrence. After progression or recurrence,
limited therapeutic options were available until 2014, when
the NCCN guidelines were updated to include the preferred
use of single-agent ramucirumab (Category 1 evidence)
with the existing recommendations for single-agent che-
motherapy (e.g., paclitaxel, docetaxel, irinotecan) [3].
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Although data are not yet available related to the real-
world use of ramucirumab, the data from claims and
electronic medical records can inform practitioners and
researchers regarding the care and cost of individuals di-
agnosed with gastric cancer.
The primary objective of this descriptive study was to
explore chemotherapy treatment patterns, healthcare re-
source utilization, costs, and outcomes for patients in the
U.S. diagnosed with gastric cancer in an electronic medical
record and administrative database, respectively.
Methods
Data sources
Electronic medical record (EMR) data were obtained from
the IMS Health Oncology Database, which is an integrated
database consisting of oncology EMR. The database contains
de-identified biomedical data from more than 740,000 cancer
patients who received care from approximately 550 providers
in 737 facilities, representing cases from all 50 U.S. states.
Administrative claims data were obtained from the
Truven Health MarketScan Research Databases, which
include person-specific clinical utilization, expenditures,
and enrollment across inpatient, outpatient, prescription
drug, and carve-out services. The database links paid
claims and encounter data to patient information across
sites and types of providers and over time, and includes
private-sector health data from approximately 100 payers
and more than 98 million patients.
Both databases provide longitudinal data from clinical
practices as part of routine clinical care across the U.S.
Eligibility criteria
Patients age 18 or older with a new diagnosis of gastric
cancer (ICD-9-CM 151.0–151.9) between January 1, 2004
and March 31, 2012 (administrative database) or between
January 1, 2004 and January 1, 2012 (EMR database) were
eligible for inclusion. The first occurrence of the eligible
ICD-9 code was defined as the ‘‘index diagnosis.’’ Patients
were ineligible if they had any evidence of cancer within
6 months before the index diagnosis or if they had any
evidence of gastrointestinal stromal tumor (ICD-9-CM
238.1) at any time. Continuous medical benefits for
6 months before the index diagnosis were required for
eligibility of patients in the administrative dataset.
Demographic and clinical variables
Demographic data in both databases include age, gender,
diagnoses (ICD-9 codes), and dates of service associated
with each diagnosis. The EMR database further contains
patient ethnicity, tumor stage, ECOG performance status
data, and laboratory tests. The databases also include in-
formation on insurance status (EMR data) or insurance
type and plan information (administrative data).
Resource use and cost variables
Administrative claims data include detailed records for
hospital inpatient admissions, outpatient medical claims,
professional claims (private physician offices or stand-
alone infusion centers), and service and facility files, with
additional information such as the length of stay at spe-
cialized nursing facilities, date and duration of service
(e.g., length of stay for hospital admissions) for medical
claims, provider type and place of service, and plan pay-
ment and patient copayment amounts. The administrative
data also include pharmacy claims, which report national
drug codes (NDC), therapeutic class of the agent admin-
istered or provided, dispense date, the quantity and days
supplied, and plan payment and patient copayment
amounts. ICD-9, Healthcare Common Procedure Coding
System (HCPCS), NDC, and Current Procedural Termi-
nology (CPT) codes were used to identify chemotherapy,
radiation therapy, surgical procedures, and other supportive
care medications used. Costs were obtained from third-
party payment data fields and adjusted for inflation and
reported in 2012 U.S. dollars, using the medical care ser-
vices component of the Consumer Price Index. Because of
the possible underestimation of costs and/or resource use
data, cost analyses excluded cases with Medicare supple-
ment and capitated claims and resource use excluded cases
with Medicare supplement claims. Resource use in the
EMR data was limited to therapeutic regimens including
each molecule and generic drug name, dose(s), date(s) of
administration, and length of therapy. Surgical procedures
were identified by HCPCS and ICD-9 procedure codes
specific to gastric/gastroesophageal-related procedures.
To simplify the data, individual chemotherapy and
biologic agents were collapsed into drug classes as follows:
biologic/targeted agents included bevacizumab, cetuximab,
crizotinib, everolimus, dasatinib, imatinib, gefitinib, so-
rafenib, sunitinib, pazopanib, regorafanib, panitumumab,
and rituximab. Platinum agents included cisplatin, oxali-
platin, and carboplatin. Taxanes included docetaxel, pa-
clitaxel, and nab-paclitaxel. Anthracyclines included
epirubicin, daunorubicin, doxorubicin, and mitoxantrone.
Alkalating agents included cyclophosphamide, ifosfamide,
melphalan, chlorambucin, mitomycin, and thiotepa. An-
timetabolites included gemcitabine, hydroxyurea,
methotrexate, fludarabine, cladribine, and pemetrexed.
Topoisomerase inhibitors included irinotecan, etoposide,
damptothecin, and topotecan. Vinca alkaloids included
608 L. M. Hess et al.
123
vincristine, vinblastine, and vinorelbine. Fluororpyrimidi-
nes included fluorouracil and capecitabine. Other smaller
groupings included folic acid analogues (leucovorin) and
hydrazine/triazines (dacarbazine, procarbazine). All other
antineoplastic agents were put into the category of ‘other.’
Concomitant medications were similarly grouped into the
following categories: hematopoietic agents, transfusions,
antibiotics, antivirals, anti-emetics, antifungal agents, anti-
infectives, pain medications, nutritional supplements, bis-
phosphonates, and hormonal agents (complete medication
lists available by request from the authors).
Analysis plan
Patient demographic and clinical characteristics assessed
at the gastric cancer index date, depending on the data-
base, included age, sex, stage, race, primary location of
tumor, performance status, length of follow-up, and in-
surance plan status. All analyses were descriptive and
exploratory in nature and were conducted using SAS 9.2.
All variables were summarized descriptively through the
tabular and graphical display of mean values, medians,
ranges, and standard deviations (SD) of continuous vari-
ables of interest and frequency distributions for catego-
rical variables. No tests of statistical significance were
planned or performed as part of this study because it was
descriptive in design.
Survival was estimated in the IMS database using the
last occurrence of a record in the database as a proxy for
date of death of each patient. This strategy has been used
previously with IMS data. Patients who reached the end of
the database were censored from the analysis. Survival
estimates were reported as number of days from the date of
diagnosis to the proxy date of death and were reported as
mean, SD, range, median, and interquartile range values for
the entire gastric cancer population, by stage of disease,
and for patients who received chemotherapy. Survival was
also estimated for patients who had a second line of che-
motherapy from the date of start of the second line of
therapy to the proxy date of death.
Average monthly costs were defined as the total per-
patient costs divided by number of months within the time
period for which the patient’s total costs were calculated.
This approach was used because of the varying survival of
patients with gastric cancer and different periods of che-
motherapy treatment (resulting in inconsistent follow-up
periods). Average total cost of care was defined as the all-
cause cost for healthcare from the time of the index diag-
nosis to the end of the database, regardless of the duration
of follow-up and regardless of disease status. To stan-
dardize differential follow-up time periods, average
monthly costs were also reported for the total cost of the
care period.
Missing data were included as a categorical field
(missing or unknown). No imputation was made to account
for incomplete data. Patients with partial data were in-
cluded in analyses for which there are complete data to
retain sample size; as a result, cases were not fully ex-
cluded as a result of missing data.
Results
There were 5257 and 11,891 patients identified meeting all
eligibility criteria in the EMR and administrative claims
datasets, respectively. Table 1 presents the baseline de-
mographic and clinical characteristics of the two sets of
patient data. This table demonstrates that there were con-
siderable missing data in the EMR system for disease stage,
performance status, and insurance status. Additionally, the
two data sources collect slightly different types of infor-
mation (e.g., clinical information is recorded in the EMR
data whereas resource utilization and cost data are only
available in the administrative data).
There was evidence of chemotherapy treatment for
37.7 % (n = 1982) and 44.6 % (n = 5299) of patients in
the EMR and administrative data, respectively. In both
databases, most patients were treated with platinum- and/or
fluoropyrimidine-containing regimens in the first line
(89.7 % and 88.7 % in the EMR and administrative
databases, respectively). Of patients receiving first-line
chemotherapy, 42.3 % received additional lines of therapy
in the EMR database, and 54.5 % received additional lines
of therapy in the administrative database. In the EMR
database, of all patients who received first-line therapy, 838
(42.3 %) went on to second-line treatment, 358 (18.1 %)
went on to receive third-line treatment, and 157 (7.9 %)
went on to receive a fourth line of therapy. In the EMR
database, a total of 131 unique drug combinations were
identified in second-line therapy, and in the administrative
data, 351 unique drug combinations were used in the sec-
ond-line setting. The unique combinations were collapsed
into drug class groupings and are summarized in Fig. 1 and
in Table 2, which demonstrate the consistency in the
classes of drugs used by line of therapy for gastric cancer
between the two data sources, despite the variety in drug
combinations used in the second line. There was no stan-
dard treatment regimen that was commonly used following
the first line of therapy; however, the same agents used in
the first line tended to be used in the second line in a wider
variety of combinations. Although irinotecan-based treat-
ment occurred in 284 (9.8 %) as second line, it was used
inconsistently with a wide variety of combinations (e.g.,
the most common combinations included platinum,
fluoropyrimidines, and/or taxanes). The wide variation in
irinotecan use resulted in the finding that no specific
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Table 1 Patients eligible for inclusion




N = 5257 N = 11,891
Mean age (SD) 64 (13) 65 (13.9)
Gender, n (%)
Male 3197 (60.8) 7427 (62.5)
Female 2059 (39.2) 4464 (37.5)
Unknown 1 (0.02) 0 (0)
Health plan, n (%)
Commercial 59 (1.1) 5881 (49.5)
Medicaid 104 (2.0) –
Medicare 4 (0.1) 6010 (50.5)
Unknown 5090 (96.8) 0 (0.0)
Specific plan type, n (%)
Comprehensive – 3217 (27.1)
Exclusive provider organization (EPO) – 90 (0.8)
Health maintenance organization (HMO) – 1773 (14.9)
Non-capitated point of service (POS) – 694 (5.8)
Capitated point of service (cPOS) – 73 (0.6)
Preferred provider organization (PPO) – 5373 (45.2)
Consumer-driven health plan – 163 (1.4)
Unknown 508 (4.3)
Site of gastric diagnosis, n (%)
Malignant neoplasm of the stomach (ICD-9, 151.x) 1 (0.02) 243 (2.0)
Malignant neoplasm of the cardia, including cardiac orifice, cardio-esophageal
junction (ICD-9, 151.0)
751 (14.3) 3695 (31.1)
Malignant neoplasm of pylorus, including prepylorus, pyloric canal (ICD-9, 151.1) 56 (1.1) 0 (0.0)
Malignant neoplasm pyloric antrum, includes antrum of stomach NOS (ICD-9,
151.2)
277 (5.3) 987 (8.3)
Malignant neoplasm, fundus of stomach (ICD-9, 151.3) 215 (4.1) 346 (2.9)
Malignant neoplasm, body of stomach (ICD-9, 151.4) 567 (10.8) 970 (8.2)
Malignant neoplasm, lesser curvature, unspecified (ICD-9, 151.5) 190 (3.6) 238 (2.0)
Malignant neoplasm, greater curvature, unspecified (ICD-9, 151.6) 116 (2.2) 189 (1.6)
Stomach, unspecified, including carcinoma ventribuli, gastric cancer (ICD-9 151.9) 2689 (51.2) 4506 (37.9)
Stage at diagnosis, n (%)
Stage 0 7 (0.1) –
Stage I 251 (4.8)
Stage II 295 (5.6) –
Stage III 345 (6.6) –
Stage IV 682 (13.0) –
Unknown 3677 (69.9) –
Charlston Comorbidity Index score at index diagnosis, mean (SD) – 2.58 (2.81)
ECOG performance status, n (%)
0 331 (6.3) –
1 444 (8.4) –
2 156 (3.0) –
3 29 (0.6) –
4 2 (0.04) –
Unknown 4295 (81.7) –
Duration of follow up from index diagnosis, mean (SD) days 607.4 (652.6) 577 (607)
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irinotecan-based regimen was used in more than 2.5 % of
the study population (these regimens are all in the ‘other’
category of Fig. 1). Post hoc analyses exploring trends in
treatment patterns could not identify any clear changes
from the earlier time period (2004–2009) to treatment in
2010 and later; treatment patterns remained heterogeneous
throughout the study period.
The duration of chemotherapy was also relatively brief.
In the EMR data, first-line therapy was administered for an
average of 63.2 days (SD = 64 days) and second-line
therapy for an average of 57.3 days (SD = 75 days). In the
administrative claims data, the duration of first-line therapy
was an average of 53.5 days (SD = 63.4 days), and the
duration of second-line therapy was 41.2 days
(SD = 55.7 days). Given that most regimens are admin-
istered on an every 21- or 28-day cycle, this represents an
average of less than three cycles of chemotherapy before
the treatment was discontinued. The estimated survival of
patients by stage at diagnosis is presented in Fig. 2. As
would be expected, survival decreases with advancing
disease stage. Estimated survival data were only available
using the last record in the database as a proxy in the EMR
data.
Resource utilization data were available in the admin-
istrative database only. Of those who received che-
motherapy, surgical procedures were identified in 879
(16.6 %) patients during chemotherapy treatment and 1484
(28.0 %) outside the chemotherapy treatment period. Sur-
gical procedures were identified in 328 (6.2 %) of those
who did not have evidence of chemotherapy. Concomitant
prescription medication use and hospitalization rates reflect
the biology and burden of the disease and its treatment on
patients. In the administrative data, 76.9 % (n = 4077) of
patients treated with chemotherapy for gastric cancer re-
ceived anti-emetics, 75.3 % (n = 3992) received pain
medication, and 56.8 % (n = 3012) received antibiotics.
During first-line therapy, 708 (13.4 %) patients were hos-
pitalized. During second-line therapy, 8.6 % of patients
Table 1 continued




N = 5257 N = 11,891
Evidence of chemotherapy, n (%) 1982 (37.7) 5299 (44.6)
Lines of therapy (of those receiving chemotherapy)
Mean (SD) 1.76 (1.28) –
Received 1 or more lines, n (%) 1982 (100) 5299 (100)
Received 2 or more lines, n (%) 838/1982 (42.3) 2888/5299 (54.5)
Received 3 or more lines, n (%) 358/1982 (18.1) 1598/5299 (30.2)
SD standard deviation, ECOG Eastern Cooperative Oncology Group, NOS not otherwise specified
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(n = 247) were hospitalized. Emergency room visits were
not uncommon during first- and second-line treatment.
During first-line therapy, 991 (18.7 %) patients went to the
emergency room. Many patients experienced multiple
visits, with a total of 1787 visits recorded during first-line
therapy. A similar pattern was evident in the second-line
setting; a total of 345 patients (12.0 %) receiving second-
line therapy experienced a total of 572 emergency room
visits during the treatment period.
There was also considerable variability in the cost of the
care of these patients, both from a third-party payer per-
spective and from a patient perspective (i.e., out of pocket
costs). All-cause cost data during first- and second-line
therapy are presented in Table 3. Patient out-of-pocket costs
averaged $926.11 (SD = $1771.90) during first-line therapy
and $646.93 (SD = $3262.49) during second-line therapy
(Table 4). In addition to the costs incurred during che-
motherapy, there were substantial costs of care following
discontinuation of chemotherapy. An average of $80,148.07
(SD = $161,421.80) in all-cause total healthcare costs were
incurred from the time of completion of chemotherapy to
death or the end of the patient record in the database. For the
1630 patients with hospitalizations after completion of
chemotherapy, the total cost of these inpatient stays was an
average of $85,769.49 (SD = $178,096.47) per patient.
Discussion
Gastric cancer is a disease with poor survival outcomes and
is associated with a lack of standard treatment strategies,
particularly following first-line therapy. Patients and the
healthcare system incur financial burdens associated with
this disease, although the range of expenses is consider-
able, with some patients incurring no costs and others ex-
periencing what could be detrimental financial burdens.
Although specific analyses were not conducted comparing
hospital versus physician office chemotherapy infusion
because of the bundling of costs in the hospital billing
systems, this study suggests there may be differences to the
patient that are not concordant with the direction of cost
burden to the third-party payer. The median out-of-pocket
cost for cancer care to a patient is numerically lower in the
hospital setting, yet is higher for the third-party payer, and
vice versa. Additional study is needed to understand the
impact of trends in the delivery of cancer care on patient
healthcare expenditures.
Fig. 2 Median estimated survival by stage: electronic medical record
data (N = 1533)
Table 2 General classes of chemotherapy agents (number and percent) used alone or in combination
Electronic medical record (EMR) data Administrative claims data
First-line therapy, n 1982 5299
Biologic, n (%)a 154 (7.8) 435 (8.2)
Taxane, n (%)a 495 (25.0) 1505 (28.4)
Anthracycline, n (%)a 408 (20.6) 880 (16.6)
Fluoropyrimidine, n (%)a 1499 (75.6) 3521 (66.4)
Platinum, n (%)a 1095 (55.2) 3294 (62.2)
Second-line therapy, n 838c 2831c
Biologic, n (%)b 103 (12.2) 340 (12.0)
Taxane, n (%)b 243 (29.0) 742 (26.2)
Anthracycline, n (%)b 137 (16.3) 381 (13.5)
Fluoropyrimidine, n (%)b 517 (61.7) 1679 (59.3)
Platinum, n (%)b 412 (49.2) 1387 (49.0)
Percent values will exceed 100 for the columns because of drug combinations used in a patient’s line of therapy
a Percent from total number of patients receiving first-line therapy
b Percent from total number of patients receiving second-line therapy
c Ns may be smaller as a result of consolidated regimen calculations
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Data used for this study were collected as part of
routine clinical or business practices and were not de-
signed to measure or study follow-up or longitudinal
care. Identification of disease was only possible using
ICD-9 codes, which do not record pathology information
about the disease. Although we excluded gastrointestinal
stromal tumors (GIST), which are traceable with ICD-9
codes, there are other subtle pathologies not detectable by
ICD-9 coding that may have added clarity to the
heterogeneity of treatments seen in this study. Subtle
differences in the number of regimens or rates of post-
first-line therapy in the different databases could be
caused by differences in the data source, rather than
actual treatment pattern differences, but it is not possible
to investigate this given the limitations of the data
sources. If a patient changed the site of care to an on-
cologist whose EMR data are not uploaded to the IMS
system, the care of that patient would no longer be
captured, in contrast to administrative data, when one
knows if a patient’s coverage has ended and if the claims
are no longer being captured in that system. Similarly,
only required fields are routinely entered, and missing
data are a concern when using EMR systems that do not
require practitioners to complete all data fields. Required
fields in EMR and claims data are limited and typically
do not capture over-the-counter medication use, response
to therapy, or dates of disease progression. Assumptions
were required to be made for the date of death and line
of therapy as a consequence of database limitations.
Other than data collection issues inherent to EMR and
administrative data, the findings of types of drugs and
treatment patterns appear highly consistent, demonstrat-
ing the heterogeneity of treatment patterns in subsequent
lines of therapy.
Table 3 Third-party payer costs for gastric cancer patient care
Third-party all-cause cost of care First-line therapy Second-line therapy
n=2820 n=1708
Overall total healthcare costs
Mean (SD) $40,810.87 ($49,916.01) $26,587.75 ($33,300.96)





Mean (SD) $18,517.92 ($27,210.54) $14,612.82 ($15,397.34)




Total healthcare costs 
associated with chemotherapy 
infusions in a hospital setting
Mean (SD) $22,882.45 ($32,904.68) $18,165.57 ($24,896.13)
Median (range) $10,505.20 ($15.36-$354,327.36)
$10,999.72 ($1.77-
$225,605.04)
Overall monthly healthcare 
costs associated with 
chemotherapy infusions in a 
hospital setting
Mean (SD) $10,304.69 ($11,302.95) $11,208.09 ($13,522.45)
Median (range) $6666.92 ($8.64-$105,377.48) $6896.82 ($1.77-$112,802.52)
n=475 n=166
Total healthcare costs for 
inpatient hospitalization 
Mean (SD) $23,944.36 ($57,783.81) $16,880.02 ($15,503.53)




Total healthcare costs 
associated with chemotherapy
in a non-hospital setting
Mean (SD) $11,798.54 ($17,026.02) $8911.08 ($13,222.77)
Median (range) $5117.36 ($4.86-$163,670.15) $3877.75 ($2.21-$103,213.25)
Monthly healthcare costs 
associated with chemotherapy
in a non-hospital setting
Mean (SD) $4677.10 ($4962.45) $4386.78 ($5014.25)
Median (range) $2997.91 ($3.35-$39,914.33) $2665.46 ($2.21-$38,189.67)
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Despite the differences in data sources and their re-
spective limitations, this study does provide details about
the treatment and follow-up care of patients diagnosed with
gastric cancer in the U.S. across very large sample sizes.
Gastric cancer is diagnosed in only about 22,220 patients
per year, so access to longitudinal data from a cohort of
more than 16,000 patients is valuable and contains im-
portant insights. A strong, consistent finding is the lack of
standardization of treatment regimens after first-line ther-
apy. Although the majority of patients received platinum
and/or fluoropyrimidines in the first-line setting, more than
350 unique treatment regimens were identified in the sec-
ond line in the administrative data. The number of regi-
mens (n = 131) was also high in the EMR data, but may be
streamlined as a result of the more limited data provided on
specific chemotherapy treatments administered to patients
(e.g., claims data provide evidence of all antineoplastic
drugs administered and billed). However, even when
grouping by therapeutic class, the variability remained
high. The regimens used in this study suggest that the care
that gastric patients receive after disease progression or
recurrence is largely not evidence based, and treatment
varies considerably. Few patients received treatments
supported by randomized trial data, which included taxanes
and irinotecan during the study period, in the setting of
second-line gastric cancer. It may be in part the conse-
quence of the lack of strong phase III data that a large
amount of heterogeneity was observed during this time
period.
The survival data was estimated and the analysis was
limited to a subset of patients with stage data at baseline.
Although these data are directionally consistent with the
trend in SEER (Surveillance, Epidemiology, and End Re-
sults program) data, which show 5-year relative survival
rates of 64.1 %, 28.8 %, and 4.2 % for localized, regional,
and distant disease, respectively [4], they are limited to a
Table 4 Patient out-of-pocket expenses
All-Cause Patient Out-of-Pocket Cost of Care First-line therapy Second-line therapy
n=2820 n=1708
Overall total out of pocket 
costs
Mean (SD) $926.11 ($1771.90) $646.93 ($3262.49)
Median (range) $374.29 ($0-$33,513.66) $139.45 ($0-$127,282.41)
Overall monthly out of pocket 
costs
Mean (SD) $424.44 ($828.13) $342.87 ($1681.08)
Median (range) $199.95 ($0-$22,941.49) $102.60 ($0-$63,641.20)
n=679 n=415
Total out of pocket costs 
associated with chemotherapy 
infusions in a hospital setting
Mean (SD) $155.31 ($513.46) $148.18 ($475.78)
Median (range) $0.00 ($0-$5910.50 ) $0.00 ($0-$4012.37)
Overall monthly out of pocket 
costs associated with 
chemotherapy infusions in a 
hospital setting
Mean (SD) $81.07 ($312.45) $90.77 ($301.69)
Median (range) $0.00 ($0-$3507.89) $0.00 ($0-$2239.80)
n=475 n=166
Total out of pocket costs for 
inpatient hospitalization 
Mean (SD) $254.54 ($642.60) $226.20 ($503.73)
Median (range) $0.00 ($0-$6646.75) $0.00 ($0-$3258.90)
n=2086 n=1204
Total out of pocket costs 
associated with chemotherapy
in a non-hospital setting
Mean (SD) $215.75 ($826.15) $120.42 ($441.63)
Median (range) $0.00 ($0-$21,680.87) $0.00 ($0-$5125.11)
Monthly out of pocket costs 
associated with chemotherapy
in a non-hospital setting
Mean (SD) $91.09 ($295.34) $60.31 ($245.06)
Median (range) $0.00 ($0-$4670.84) $0.00 ($0-$4099.51)
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small portion of the study population with stage data and
are likely not representative of the gastric cancer popula-
tion. It is unknown if other factors (such as receipt of
surgery or chemotherapy treatment) made it more likely for
this field to be populated in the EMR data.
Several recent randomized trials have been published
demonstrating improved survival outcomes in the second-
line setting for single-agent therapy [5–8]. These trials have
primarily evaluated single-agent docetaxel, irinotecan,
docetaxel, and ramucirumab. In addition to ramucirumab
monotherapy [5], research has also recently demonstrated
improved survival for the combination of ramucirumab
plus paclitaxel versus single-agent paclitaxel in gastric
cancer [9]. It will be of interest to examine how the
emergence of these phase III trial data and the availability
of new FDA-approved products, such as ramucirumab,
may influence treatment patterns in the future. The data
collected for the current study preceded the availability of
these publications. Future research should evaluate the
influence of this new evidence in the treatment patterns for
the second-line treatment of gastric cancer and could build
on this work by studying comparative effectiveness of
these treatment regimens in the second line. Future re-
search could build on this initial work as well to understand
the cost-effectiveness of various regimens and sequences of
care to inform treatment decision making for the care of
these patients.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
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